​Technology

​

Najít Technologies, Inc. utilizes a novel oxidation-based vaccine platform termed, HydroVax™.  This platform technology results in superior vaccine formulations for several infectious diseases. Based on this foundation, NTI recently developed a next-generation, site-directed oxidation approach that represents a major advancement in this vaccine technology and the company has multiple patents and pending patent applications under review.

 

HydroVax™ vaccines:

• Replace live vaccines with an inactivated counterpart, thereby reducing the risk for serious adverse events

• Preserve important immunologic epitopes including neutralizing epitopes and T cell epitopes

• Are amenable to heat-stable, preservative-free formulations

 

The properties inherent to our vaccine development platform make them ideal candidates for use in developing countries in which an effective cold-chain is often difficult to establish. In addition, because the HydroVax family of vaccines are inactivated, they are suitable for immunizing vulnerable populations such as the very young, the elderly and the immunocompromised – individuals in which live virus vaccines may be contraindicated. We are interested in applying our platform to the development of safe and effective vaccines against emerging infectious diseases — especially serious diseases that pose a threat to the American Warfighter as well as international travelers and vulnerable individuals living in endemic countries.

​

To date, NTI has 15 issued vaccine development patents related to our advanced oxidation-based inactivation technology and the use of polyatomic oxyanions to prevent epitope damage during inactivation procedures involving peroxide, formaldehyde or betapropiolactone (BPL). A list of our current issued patents is provided below:​

 

Inactivating Pathogens and Producing Highly Immunogenic Vaccines Using a Dual Oxidation Process

• US Patents: 12,102,676 B2; 11,633,470 B2; 11,141,475 B2

• International Patents: Europe – EP3454894; Canada – CA3022603; Japan – JP2019515047; Australia – AU2017261706; India – 201817041609

 

Inorganic Polyatomic Oxyanions for Protecting Against Antigenic Damage During Pathogen Inactivation for Vaccine Production

• US Patents: 11,844,832 B2; 10,744,198 B2

• International Patents: Europe – EP3454895; Canada – CA3022602; Japan – JP2019515046; Australia – AU2017261705; India – 201817041610